Sphingotec

Name: Sphingotec
Address: Neuendorfstraße 15 A, Hennigsdorf, 16761, DE
Telephone: +493302205650
Price range: Not Applicable

Anrufen Wegbeschreibung Website Service kontaktieren

SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. https://sphingotec.com/

Our aspiration is to effectively translate scientific advancements into routine clinical practice. Our innovative biomarkers address diagnostically underserved critical care conditions such as sepsis, acute heart failure, acute kidney injury, and cardiogenic shock. We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10. The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings.

22/10/2026

Thank you, Leipzig! 🙏
Our CEO and Managing Director Deborah Bergmann has just pitched SphingoTec in the “National Heroes” session at the Finance Day – Wachstumskapital für die Life Sciences.
Five minutes is short, but it was enough to share our message: in critical care, every hour counts. Our proprietary biomarkers support faster, better-informed decisions, both as stand-alone markers and as companion diagnostics that enable a personalized medicine approach.
We’re grateful for the chance to represent SphingoTec among such an inspiring group of life sciences companies, and for the questions from the audience. Thank you to Viola Bronsema for moderating, and to GoingPublic Media and Plattform Life Sciences for a well-organised event that brings companies and investors together.
The conversations continue through the afternoon and at the evening event. If you’d like to talk about growth plans, financing or partnerships, find Deborah or Nicole at the venue or message us here.

21/10/2026

📍 Kidney Week 2026: penKid in the spotlight
Can a simple blood test help us spot severe kidney injury before it gets worse? That is the question behind a poster at ASN Kidney Week 2026 in Denver, CO, featuring our biomarker penKid.

📄 “Proenkephalin Predicts Severe AKI in High-Risk Patients”
🗓 22 October 2026, 10:00 AM-12:00 PM
📍 Exhibit Hall A, Convention Center, Denver
🔬 Session: AKI: Prevention, Diagnostics, and Management

Acute kidney injury (AKI) can develop quickly in hospitalized patients, and standard markers may not identify patients at risk of progression at an early stage.
In a study of 167 hospitalized patients already at increased risk for severe AKI, penKid (proenkephalin A 119-159) was measured in blood samples taken in the first two days after admission.
Early penKid levels helped identify the patients most likely to develop persistent severe AKI or need kidney replacement therapy. Results were particularly pronounced in ICU patients.
Are you at Kidney Week? Stop by Exhibit Hall A to see the poster. Not there? Message us and we’ll gladly share more.

20/10/2026

📣 See you in Leipzig: On 22 October, SphingoTec will be part of the Finance Day – Wachstumskapital für die Life Sciences at BIO CITY Leipzig. Our CEO and Managing Director Deborah Bergmann and Nicole Witzmann (CFO) will be on site, and we’re proud to be among the selected companies pitching in the “National Heroes” session.

🎤 Pitch session “National Heroes”
🗓 22 October 2026, 14:15–15:00
📍 BIO CITY Leipzig

In critical care, every hour counts. Our proprietary biomarkers give clinicians the signal they need, both as stand-alone tests and as companion diagnostics that help match the right patient to the right therapy. Deborah will share how this positions SphingoTec at the intersection of diagnostics and personalized medicine, along with our milestones and our plans for growth and financing.
If you’re an investor or finance professional looking at diagnostics and precision medicine, we’d love to meet you. Send us a message or find us on the day.
Thank you to GoingPublic Media and Plattform Life Sciences for the invitation.

14/10/2026

💡 “penKid adds value beyond serum creatinine in sepsis, enabling earlier and more granular risk stratification for renal deterioration and short-term mortality.”
That is the conclusion of new data presented at ESICM LIVES 2026. In a secondary analysis of the multicenter Next GeneSiS trial, researchers from University Hospital Essen and partners looked at 492 patients with sepsis or septic shock. They asked whether penKid (Proenkephalin A 119-159) together with serum creatinine improves renal risk assessment.
The take-aways:
🔹 penKid provides substantial added value beyond serum creatinine in predicting worsening renal function and poor outcome.
🔹 Patients with an isolated elevation of penKid, with serum creatinine still in the normal range, are easy to miss with creatinine alone. This group had the highest 28-day mortality, at 54.2%.

These findings from a contemporary, prospective multicenter cohort are consistent with the recent patient-level meta-analysis by (Arlt, B. et al.,2026) and support the incremental prognostic value of penKid in conjunction with serum creatinine for predicting worsening renal function and mortality in sepsis.
Poster presented by Jonas Gregorius from University Hospital Essen.
📍 “Clinical performance of Proenkephalin A 119-159 in conjunction with serum creatinine for renal risk assessment in patients with sepsis or septic shock - a secondary analysis of Next GeneSiS-Trial”

09/10/2026

Meet SphingoTec at ESICM LIVES 2026 in Lisbon!
SphingoTec joins the critical care community at ESICM LIVES 2026, October 10-14. Our CEO and Managing Director Deborah Bergmann, our Medical Affairs Director Martina Kalle-Brune and our Medical Science Liaison Manager Marlene Gotschalk will be on site and open for discussions on kidney function assessment in critically ill patients, the latest clinical evidence on penKid and future collaborations.
On Monday, October 12, we're looking forward to joining our partner Boditech Med's Expert Meeting, with insightful discussions on the latest innovation, the AFIAS sphingotest® penKid®.
There's more to look forward to: researchers from University Hospital Essen will present new penKid research in sepsis and septic shock, a secondary analysis of the Next GeneSiS trial, which we are proud to have contributed to. Details to follow!
Would you like to meet us in Lisbon? Send us a message and we'll find time to connect.
📍 Lisbon, Portugal | 📅 October 10-14, 2026

07/10/2026

Kidney health takes center stage in Leipzig this week.
SphingoTec is at the Kongress für Nephrologie (DGFN), October 8-11, 2026. Our CEO and Managing Director Deborah Bergmann and our Medical Affairs Director Martina Kalle Brune are looking forward to discussing advances in kidney function biomarkers with the nephrology community and laying the foundations for future collaborations.
If you're at DGFN, reach out and let's find a time to talk.
📍 Leipzig, Germany | 📅 October 8-11, 2026

06/10/2026

New Study Suggests Potential of penKid in Kidney Reserve Assessment

PenKid has been evaluated for the first time as a marker of kidney functional reserve (KFR): a new study in Physiological Reports found that its response spanned a much wider range than cystatin C and creatinine clearance after a protein stimulus. The study in 62 participants marks the first published evaluation of penKid for this use.
Read the press release here: https://www.sphingotec.eu/new-study-suggests-potential-of-penkid-in-kidney-reserve-assessment

17/09/2026

👋 Welcome to the team, Dr. Marlene Gottschalk!
We’re pleased to welcome Dr. Marlene Gottschalk as Medical Science Liaison Manager at SphingoTec.
Marlene joins us from translational research at the LIMES Institute, University of Bonn, where she worked at the interface of preclinical science, scientific communication, and cross functional stakeholder collaboration.
At SphingoTec, Marlene will connect with the scientific and clinical community to advance dialogue around organ function biomarkers in critical care—especially penKid for kidney function in conditions such as AKI, sepsis and acute heart failure.
Her focus: meaningful scientific exchange with clinicians and researchers, supporting evidence generation, and bringing real world insights back into our medical strategy.

16/09/2026

🔬 SphingoTec at DGAI 2026 – Kassel
Our Medical Affairs Director Martina Kalle-Brune and Medical Science Liaison Dr. Marlene Gottschalk will be at the DGAI Jahreskongress from 16–18 September 2026 in Kassel.
At SphingoTec, we look forward to discussions with the critical care community on the latest developments in kidney function and endothelial biomarkers—especially penKid and bio‑ADM— and their role in supporting diagnosis, risk assessment, and patient monitoring in acute care settings including sepsis, acute heart failure and acute kidney injury (AKI).
If you’re attending DGAI, feel free to reach out to arrange a meeting during the congress.

27/08/2026

We are excited to announce the publication of new real-world data on proenkephalin A 119–159 (penKid) in critically ill patients. The data, published in Annals of Intensive Care, add to the growing body of evidence supporting penKid as a functional biomarker for kidney function and help inform clinical decision-making in AKI and KRT.
✅ In a prospective, real-world study of 1,436 critically ill ICU patients, penKid provided clinically relevant information across AKI severity and during kidney replacement therapy (KRT).
✅ PenKid addressed a key unmet need in KRT management by identifying, with greater precision than standard biomarkers, patients at high risk of KRT liberation failure – helping to avoid stopping therapy too early.
✅ The findings support a future role for penKid in helping to standardize one of the few intensive care processes where the need for better decision support is widely acknowledged and current tools remain insufficient.

👉Read more in the press release: https://www.sphingotec.eu/new-real-world-data-show-penkid-adding-decision-support-for-kidney-replacement-therapy-in-critical-care
👉 Read the full publication: https://www.sciencedirect.com/science/article/pii/S2110582026001482

Adresse

Neuendorfstraße 15 A
Hennigsdorf
16761

Telefon

+493302205650

Website

http://www.sphingotec.de/

Benachrichtigungen

Erfahren Sie als Erste/r von Neuigkeiten und Aktionen: Wir schicken Ihnen eine E-Mail, wenn Sphingotec etwas veröffentlicht. Ihre E-Mail-Adresse wird für keinen anderen Zweck verwendet, und Sie können sich jederzeit abmelden.